公开(公告)号：US20240261371A1

公开(公告)日：2024-08-08

申请号：US17999903

申请日：2021-05-27

申请人： JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD.

发明人： Wei XIAO ,  Deshan LI ,  Dan YU ,  Zhihang LIU ,  Zhenzhong WANG ,  Chengkai YIN ,  Xu SUN

IPC分类号： A61K38/18 ,  A61P3/10 ,  C07K7/06 ,  C07K14/50

CPC分类号： A61K38/1825 ,  A61P3/10 ,  C07K7/06 ,  C07K14/50 ,  C07K2319/31

摘要： A recombinant human fibroblast growth factor 21 (rhFGF21) fusion protein, a polynucleotide encoding the rhFGF21 fusion protein, a recombinant expression vector, a recombinant cell, a pharmaceutical composition and a kit containing the rhFGF21 fusion protein, a use of the rhFGF21 fusion protein, and a method for producing the rhFGF21 fusion protein. Efficient and soluble expression is achieved using a genetic engineering method to obtain a rhFGF21-(VPGXG)n fusion protein, wherein by means of fusion of rhFGF21 and an elastin-like protein (VPGXG)n having an appropriate cycle number n, the resulting fusion protein has better biological activity than wild-type rhFGF21. Moreover, experimental results indicate that the rhFGF21-(VPGXG)n fusion protein has high expression efficiency, and can effectively reduce the blood sugar level in the body of a diabetic animal. In addition, compared with wild-type hFGF21, the fusion protein also has the advantage of a long efficacy duration in reducing the blood sugar level.